enGene Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
enGene Therapeutics Inc. (ENGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 1.88 million shares for the 9-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-09-08
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-07-31 was 1.82M shares, a 193.40% increase year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-10-31 was 120.45K shares, a 122.70% increase year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-07-31 was 619.88K shares, a 569.72% increase year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-04-30 was 73.78K shares, a 31430.77% increase year-over-year.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 886.11K shares, a 503.30% increase from fiscal 2024.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 146.88K shares, a 58.18% increase from fiscal 2023.
- enGene Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 92.85K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-07-31 | 1.82M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-09-08 | 1.88M shares 10-Q · filed 2026-09-08 | ||
| 2026-04-30 | 60.99K shares 10-Q · filed 2026-06-15 | |||
| 2025-10-31 | 120.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | 740.33K shares derived: sum of 2 quarters · filed 2025-12-22 | 814.11K shares derived: sum of 3 quarters · filed 2025-12-22 | 886.11K shares 10-K · filed 2025-12-22 |
| 2025-07-31 | 619.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-09-11 | 693.66K shares derived: sum of 2 quarters · filed 2025-09-11 | 765.66K shares 10-Q · filed 2025-09-11 | 819.74K shares derived: sum of 4 quarters · filed 2025-09-11 |
| 2025-04-30 | 73.78K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-06-12 | 145.78K shares 10-Q · filed 2025-06-12 | 199.87K shares derived: sum of 3 quarters · filed 2025-06-12 | 292.43K shares derived: sum of 4 quarters · filed 2025-06-12 |
| 2025-01-31 | 72.00K shares 10-Q · filed 2025-03-10 | 126.08K shares derived: sum of 2 quarters · filed 2025-03-10 | 218.64K shares derived: sum of 3 quarters · filed 2025-03-10 | 218.88K shares derived: sum of 4 quarters · filed 2025-03-10 |
| 2024-10-31 | 54.09K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-19 | 146.64K shares derived: sum of 2 quarters · filed 2024-12-19 | 146.88K shares derived: sum of 3 quarters · filed 2024-12-19 | 146.88K shares 10-K · filed 2024-12-19 |
| 2024-07-31 | 92.56K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-09-10 | 92.79K shares derived: sum of 2 quarters · filed 2024-09-10 | 92.79K shares 10-Q · filed 2024-09-10 | |
| 2024-04-30 | 234.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-06-14 | 234.00 shares 10-Q · filed 2024-06-14 | ||
| 2024-01-31 | 0.00 shares 10-Q · filed 2024-03-11 | |||
| 2023-10-31 | 92.85K shares 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |